By Sherri Oslick --
About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Ferring B.V. v. Watson Pharmaceuticals, Inc. et al.
3:11-cv-00853; filed November 25, 2011 in the District Court of Nevada
• Plaintiff: Ferring B.V.
• Defendants: Watson Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.
Ferring B.V. v. Apotex, Inc. et al.
3:11-cv-00854; filed November 25, 2011 in the District Court of Nevada
• Plaintiff: Ferring B.V.
• Defendants: Apotex, Inc.; Apotex Corp.
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 8,022,106 ("Tranexamic Acid Formulations," issued September 20, 2011) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Ferring's Lysteda® (tranexamic acid, used to treat heavy menstrual bleeding). View the Watson complaint here.
AntiCancer, Inc. v. Leica Microsystems, Inc. et al.
3:11-cv-02756; filed November 23, 2011 in the Southern District of California
• Plaintiff: AntiCancer, Inc.
• Defendants: Leica Microsystems, Inc.; DOES 1-10, inclusive
Infringement of U.S. Patent No. 6,649,159 ("Whole-body Optical Imaging of Gene Expression and Uses Thereof," issued November 18, 2003) based on Leica's use, manufacture and sale of its FCM1000 device. View the complaint here.
Bristol-Myers Squibb Co. v. Apotex, Inc. et al.
3:11-cv-06918; filed November 23, 2011 in the District Court of New Jersey
• Plaintiff: Bristol-Myers Squibb Co.
• Defendants: Apotex, Inc.; Apotex Corp.
Infringement of U.S. Patent Nos. 6,596,746 ("Cyclic Protein Tyrosine Kinase Inhibitors," issued July 22, 2003), 7,125,875 (same title, issued October 24, 2006), 7,153,856 (same title, issued December 26, 2006), and 7,491,725 ("Process For Preparing 2-Aminothiazole-5-Aromatic Carboxamides As Kinase Inhibitors" duly and legally issued on February 17, 2009) following a Paragraph IV certification as part of Apotex's filing of a second ANDA to manufacture additional dosage forms of a generic version of Bristol-Myers' Sprycel® (dasatinib, used to treat adults chronic myeloid leukemia). View the complaint here.
Comments